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BACKGROUND: Coronary flow capacity (CFC), which is a categorical assessment based on the combination of hyperemic coro-
nary flow and coronary flow reserve (CFR), has been introduced as a comprehensive assessment of the coronary circulation 
to overcome the limitations of CFR alone. The aim of this study was to quantify coronary flow changes after percutaneous 
coronary intervention in relation to the classification of CFC and the current physiological cutoff values of fractional flow re-
serve, instantaneous wave-free ratio, and CFR.
METHODS AND RESULTS: Using the combined data set from DEFINE FLOW (Distal Evaluation of Functional Performance With 
Intravascular Sensors to Assess the Narrowing Effect -Combined Pressure and Doppler FLOW Velocity Measurements) and 
IDEAL (Iberian-Dutch-English), a total of 133 vessels that underwent intracoronary Doppler flow measurement before and after 
percutaneous coronary intervention were analyzed. CFC classified prerevascularization lesions as normal (14), mildly reduced 
(40), moderately reduced (31), and severely reduced (48). Lesions with larger impairment of CFC showed greater increase 
in coronary flow and vice versa (median percent increase in coronary flow by revascularization: 4.2%, 25.9%, 50.1%, and 
145.5%, respectively; P<0.001). Compared with the conventional cutoff values of fractional flow reserve, instantaneous wave-
free ratio, and CFR, an ischemic CFC defined as moderately to severely reduced CFC showed higher diagnostic accuracy 
with higher specificity to predict a >50% increase in coronary flow after percutaneous coronary intervention. Receiver operat-
ing characteristic curve analysis demonstrated that only CFC has a superior predictive efficacy to CFR (P<0.05). Multivariate 
analysis revealed lesions with ischemic CFC to be the independent predictor of a significant coronary flow increase after 
percutaneous coronary intervention (odds ratio, 10.7; 95% CI, 4.6–24.8; P<0.001).
CONCLUSIONS: CFC showed significant improvement of identification of lesions that benefit from revascularization compared 
with CFR with respect to coronary flow increase.
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Previous studies have shown that the benefit of re-
vascularization in patients with stable coronary artery 
disease exists along a continuum.1–3 Pressure-derived 
coronary physiological indices like fractional flow re-
serve (FFR) are commonly used as invasive markers 
to quantify the functional severity of an epicardial 
coronary artery lesion and to guide revasculariza-
tion. However, a complete description of coronary 
physiology extends beyond epicardial pressure gra-
dients.4–7 Therefore, a comprehensive hemodynamic 
assessment could augment identification of optimal 
lesions for revascularization.
Coronary flow reserve (CFR) provides a well-vali-
dated index incorporating both epicardial and micro-
circulatory contributions.8 This index associates with 
long-term adverse events.9,10 However, as a ratio of 2 
physiological conditions, CFR alone does not distin-
guish between alterations in baseline versus hyper-
emic flow. To overcome these limitations, Johnson and 
Gould introduced the concept of coronary flow ca-
pacity (CFC) as a novel, comprehensive framework for 
coronary physiology using positron emission tomogra-
phy.11 CFC is a categorical assessment based on the 
combination of hyperemic myocardial blood flow and 
CFR to classify the impairment of myocardial blood 
flow. This concept has been subsequently translated 
into intracoronary physiological assessment and found 
to offer superior prognostic efficacy for long-term clin-
ical outcomes versus CFR in deferred coronary artery 
lesions.12 This superior capacity for discriminations 
of adverse cardiovascular events sets the basis for 
aiming to use CFC as an invasive diagnostic tool. We 
hypothesized that CFC would also improve the identi-
fication of lesions that benefit from percutaneous cor-
onary intervention (PCI) with respect to coronary flow 
improvement. Thus, the aim of this study was to quan-
tify coronary flow changes after PCI in relation to the 
classification of CFC and the current cutoff values of 
conventional physiological indices.
METHODS
Study Design and Patient Population
Study data combined 2 studies. One was a subset 
of the DEFINE FLOW (Distal Evaluation of Functional 
Performance With Intravascular Sensors to Assess 
the Narrowing Effect—Combined Pressure and 
Doppler FLOW Velocity Measurements) study 
(NCT02328820).13 Another was the international mul-
ticenter pooled database from Amsterdam UMC (The 
Netherlands), Imperial College of London (United 
Kingdom), and Hospital Clinico San Carlos (Spain), 
part of which was from IDEAL study.14 In brief, the 
DEFINE FLOW study included patients with coro-
nary artery disease who had at least one epicardial 
stenosis of ≥50% diameter stenosis; the multicenter 
pooled database enrolled patients with ≥1 interme-
diate coronary stenosis (40%–70% diameter steno-
sis at visual assessment). PCI was performed only 
when both FFR and CFR values were below the es-
tablished criteria (FFR ≤0.80 and CFR <2.0) for the 
DEFINE FLOW study, while PCI was done at the 
operator’s discretion on the basis of not only FFR 
values but also impaired CFR (CFR <2.0) or angio-
graphic findings with suspicious symptoms of angina 
CLINICAL PERSPECTIVE
What Is New?
• Coronary flow capacity is a modified flow-
based comprehensive assessment of the coro-
nary circulation that improves the discriminating 
ability to predict coronary flow increase after re-
vascularization in comparison with conventional 
coronary flow reserve.
• Moderately-to-severely reduced coronary flow 
capacity has a high predictive performance with 
high sensitivity for a significant increase in coro-
nary flow compared with the conventional cutoff 
values for fractional flow reserve, instantaneous 
wave-free ratio, and coronary flow reserve.
What Are the Clinical Implications?
• Coronary flow capacity is a useful index to iden-
tify lesions that benefit from revascularization 
with respect to coronary flow increase and can 
yield incremental information in the treatment 
strategies based on the current cutoff values of 
conventional physiological indices.
• The current study provides a physiological ra-
tionale for revascularization of lesions guided by 
coronary flow capacity grading.
Nonstandard Abbreviations and Acronyms
APV average peak coronary blood flow 
velocity
CFC  coronary flow capacity
CFR  coronary flow reserve
Pa  aortic pressure
FFR  fractional flow reserve
hAPV hyperemic average peak coronary 
blood flow velocity
iFR  instantaneous wave-free ratio
PCI  percutaneous coronary intervention




 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016130. DOI: 10.1161/JAHA.120.016130 3
Murai et al CFC to Identify Coronary Flow Increase After PCI
in the pooled database that encompassed the IDEAL 
study. Subjects from both studies underwent pre-
PCI coronary physiological assessment including 
intracoronary Doppler flow measurement, but post-
PCI physiological assessment was not mandatory. 
All subjects with measurements before and after PCI 
were included in the current analysis. The exclusion 
criteria of both studies were prior coronary artery by-
pass grafting, left main coronary artery disease, sub-
total or similar high-grade lesions, and culprit lesions 
for recent myocardial infarction. The institutional eth-
ics committees for each center approved the parent 
study, and all subjects gave written informed con-
sent. The data that support the findings of this study 
are available from the corresponding author upon 
reasonable request.
Coronary Angiographic and Physiological 
Assessments
Before angiography, the operator administered intra-
coronary nitroglycerin as per routine. Coronary an-
giography was performed by standard techniques. 
All physiological measurements were performed 
using a 0.014-inch dual-sensor–equipped guidewire 
(Combowire; Philips-Volcano, San Diego, CA). For 
serial or tandem lesions in the same vessel, only a 
single physiologic study was performed distal to all 
lesions. Intracoronary physiological measurements 
including distal coronary pressure and average peak 
coronary blood flow velocity (APV) were simultane-
ously recorded during stable conditions at rest and at 
hyperemia. Hyperemia was induced by intracoronary 
adenosine administration (20–150 μg) or intravenous 
adenosine infusion (140 μg/kg per minute) through ei-
ther a central or peripheral vein. Intracoronary physi-
ological assessment was repeated after PCI.
Data Analysis
Physiological data were extracted from the digital 
archive (ComboMap, Philips-Volcano, San Diego, 
CA) and analyzed offline using a custom software 
package designed with MATLAB (Mathworks, Inc, 
Natick, MA, USA) for the IDEAL data set and in core 
laboratory using custom software Studymanager for 
the DEFINE FLOW data set by experienced analysts 
blinded to the coronary angiogram and clinical char-
acteristics. FFR was calculated as the ratio of mean 
distal coronary pressure to aortic pressure (Pa) during 
hyperemia. instantaneous wave-free ratio (iFR) is the 
ratio of distal coronary pressure/Pa measured during 
a prespecified period in mid-to-late diastole without 
hyperemia. CFR was calculated as the ratio of hy-
peremic average peak coronary blood flow velocity 
(hAPV) to basal APV. The conventional cutoff values 
of physiological indices: 0.80 for FFR, 0.89 for iFR, 
and 2.0 for CFR, which have been recommended in 
decision making in the current treatment guidelines 
of revascularization,15–17 were applied. CFC catego-
rizes vessels into 4 grades based on hAPV and CFR. 
In the present study, CFC classification was applied 
according to the criteria developed in a previous 
study as follows12: Normal CFC was defined as a CFR 
≥2.8 with corresponding hAPV of ≥49.0 cm/s. Mildly 
reduced CFC was defined as a CFR <2.8 and >2.1 
and corresponding hAPV of <49.0 and >33.0 cm/s, 
respectively. Moderately reduced CFC was defined 
as CFR ≤2.1 and >1.7 with corresponding hAPV of 
≤33.0 and >26.0 cm/s, respectively. Finally, severely 
reduced CFC was defined as a CFR ≤1.7 and cor-
responding hAPV of ≤26.0  cm/s. According to the 
design of CFC grading established in the previous 
study,12 a grading of moderately or severely reduced 
CFC was considered “ischemic” CFC in the pre-
sent study. The change in hyperemic coronary flow 
was assessed by the ratio of post-PCI hAPV to pre-
PCI hAPV. A previous positron emission tomogra-
phy study showed an average increase in coronary 
flow after PCI of 46%.18 Accordingly, we defined a 
>50% increase of peak coronary flow velocity after 
PCI (ratio of hAPV after PCI to before PCI [R-hAPV] 
≥150%) as a significant improvement. For 2 subjects 
with multivessel disease evaluated before and after 
PCI, the single vessel with the lower FFR value was 
included in this study to maintain 1 vessel/subject.
Statistical Analysis
Normality of the distribution was assessed by 
Shapiro-Wilk statistics, and the homogeneity of vari-
ances was assessed by Levene’s test. Continuous 
variables are expressed as mean±standard devia-
tion when normally distributed and as median with 
first and third quartiles (Q1, Q3) when nonnormally 
distributed. Categorical variables are presented as 
counts and percentages. Overall differences of clini-
cal, physiological, and angiographic parameters in 
the classification of CFC grading (4 categories) and 
grading of CFR based on CFC criteria were compared 
with Kruskal–Wallis, or chi-squared tests, followed by 
post hoc Mann–Whitney U, chi-squared, or Fisher’s 
exact tests with Bonferroni adjustment. Receiver op-
erating characteristic curve analysis was performed 
to compare the predictive efficacies of physiologi-
cal indices to predict lesions with R-hAPV ≥150%. 
To evaluate the incremental predictive ability of each 
physiological cutoff value added to angiographic ste-
nosis severity as a baseline model, the concordance 
index was assessed. The discriminatory ability of 
ischemic CFC added to binary conventional physi-
ological indices was assessed by the reclassifica-
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Table 1. Patient Characteristics and Physiological Parameters Before and After PCI Across CFC Grading
Total, N=133










Age, y 63.1±10.1 61.6±10.9 63.4±10.7 63.3±9.9 63.3±9.7 0.94
Male, n (%) 101 (76.0) 13 (92.9) 29 (72.5) 25 (80.6) 34 (70.8) 0.32
Lesion location RCA/LAD/
LCX, n (%)
35 (26.3)/76  
(57.1)/22 (16.5)
4 (28.6)/9  
(64.3)/1 (7.1)
10 (25.0)/25  
(62.5)/5 (12.5)
11 (35.5)/13  
(41.9)/7 (22.6)
10 (20.8)/29  
(60.4)/9 (18.8)
0.52
Hypertension, n (%) 74 (55.6) 7 (50.0) 21 (52.5) 19 (61.3) 27 (56.3) 0.90
Hyperlipidemia, n (%) 95 (71.4) 12 (85.7) 27 (67.5) 24 (77.4) 32 (66.7) 0.43
Diabetes mellitus, n (%) 40 (30.1) 3 (21.4) 12 (30.0) 7 (22.6) 18 (37.5) 0.46
Medication, n (%)
ACE-I or ARB 30 (22.6) 3 (21.4) 8 (20.0) 7 (22.6) 12 (25.0) 0.96
β-blocker 65 (48.9) 7 (50.0) 20 (50.0) 17 (54.8) 21 (43.8) 0.81
CCB 35 (26.3) 3 (21.4) 5 (12.5)* 13 (41.9)† 14 (29.2) 0.042
Statin 69 (51.9) 7 (50.0) 19 (47.5) 17 (54.8) 26 (54.2) 0.91
QCA analyses
Pre-PCI MLD, mm 1.00±0.35 1.20±0.27 1.06±0.37 0.95±0.37 0.92±0.31 0.085
Post-PCI MLD, mm 2.41±0.63 2.37±0.64 2.52±0.60 2.30±0.55 2.42±0.72 0.72
Pre-PCI RD, mm 2.60 (2.17–2.86) 2.35 (2.11–2.73) 2.65 (2.29–2.89) 2.43 (1.86–3.08) 2.61 (2.26–2.83) 0.77
Post-PCI RD, mm 2.80 (2.45–3.28) 2.67 (2.54–3.03) 3.07 (2.53–3.47) 2.60 (2.30–3.38) 2.96 (2.40–3.27) 0.68
Pre-PCI DS, % 58.5 (48.9–68.3) 49.1 (44.5–58.5)‡ 55.7 (48.6–62.2)‡ 62.8 (44.0–72.0) 66.0 (54.7–71.5)†,§ 0.006
Post-PCI DS, % 13.1 (7.5–21.9) 14.5 (7.3–19.8) 13.0 (7.3–20.6) 13.8 (9.0–22.4) 12.0 (6.0–26.2) 0.77
Physiologic parameters
Baseline
Pa at rest, mm Hg 98±16 97±15 99±15 98±17 97±1 0.98
Pd at rest, mm Hg 80±20 87±15‡ 87±17‡ 83±18‡ 71±22*,†,§ <0.001
Basal APV, cm/s 16.4 (11.9–20.4) 27.2 (19.0–38.1)*,‡ 18.1 (13.4–23.2)‡ 17.6 (10.7–19.6)§ 13.7 (10.9–16.3)†,§ <0.001
Pa at hyperemia, mm Hg 91±16 95±19 92±16 91±16 89±15 0.60
Pd at hyperemia, mm Hg 62±18 72±18‡ 68±15‡ 64±17‡ 53±17*,†,§ <0.001
hAPV, cm/s 26.8 (18.6–38.2) 57.4 (51.9–81.0)*,†,‡ 37.6 (31.5–41.6)*,‡,§ 27.4 (20.6–30.1)†,‡,§ 18.3 (12.7–22.7)*,†,§ <0.001
FFR 0.70 (0.55–0.80) 0.79 (0.70–0.82)‡ 0.75 (0.68–0.82)‡ 0.73 (0.59–0.79)‡ 0.56 (0.45–0.73)*,†,§ <0.001
iFR 0.82 (0.61–0.90) 0.86 (0.80–0.95)‡ 0.88 (0.81–0.92)‡ 0.82 (0.68–0.91)‡ 0.57 (0.37–0.85)*,†,§ <0.001
CFR 1.6 (1.3–2.1) 2.2 (1.7–3.6)*,‡ 2.2 (1.7–2.4)*,‡ 1.7 (1.4–1.9)†,‡,§ 1.3 (1.0–1.5)*,†,§ <0.001
After PCI
Pa at rest, mm Hg 99±16 98±15 99±15 100±17 98±16 0.99
Pd at rest, mm Hg 94±16 93±16 94±15 95±16 95±16 0.98
Basal APV, cm/s 19.1 (14.7–27.0) 25.8 (16.3–32.6) 19.0 (14.2–26.9) 17.0 (13.1–23.8) 18.7 (14.5–27.3) 0.22
Pa at hyperemia, mm Hg 90±17 92±15 89±18 91±17 89±16 0.91
Pd at hyperemia, mm Hg 80±17 81±17 80±18 81±17 80±16 0.99
hAPV, cm/s 42.6 (36.5–62.3) 59.3 (47.2–73.5)† 43.5 (36.7–58.5)§ 39.5 (30.9–67.5) 41.1 (32.7–66.7) 0.037
FFR 0.90 (0.85–0.97) 0.89 (0.80–0.91) 0.90 (0.86–0.94) 0.90 (0.85–0.95) 0.90 (0.86–0.95) 0.47
iFR 0.96 (0.91–0.98) 0.93 (0.89–0.97) 0.95 (0.92–0.98) 0.96 (0.92–0.99) 0.96 (0.92–0.99) 0.49
CFR 2.3 (1.9–2.9) 2.6 (2.2–3.0) 2.5 (1.8–3.1) 2.2 (1.9–3.0) 2.2 (1.8–2.7) 0.38
CFC, normal/mild/
moderate/severe, n (%)
71 (53.4)/45 (33.8)/ 
12 (9.0)/5 (3.8)
11 (78.6)/3 (21.4)/ 
0 (0.0)/0 (0.0)
23 (57.5)/14 (35.0)/ 
3 (7.5)/0 (0.0)
13 (41.9)/12 (38.7)/ 
3 (9.7)/3 (9.7)
24 (50.0)/16 (33.3)/ 
6 (12.5)/2 (4.2)
0.31
Change in physiological parameters
Absolute change in FFR 0.21±0.17 0.10±0.12‡ 0.16±0.13‡ 0.19±15‡ 0.30±17*,†,§ <0.001
Absolute change in iFR 0.11 (0.03–0.35) 0.04 (−0.01 to 0.11)‡ 0.08 (0.01 to 0.12)‡ 0.11 (0.03–0.30)‡ 0.36 (0.11–0.58)*,†,§ <0.001
Absolute change in CFR 0.6 (0.2–1.2) 0.2 (−0.4 to 0.7)‡ 0.5 (−0.1 to 1.0)‡ 0.7 (0.2–1.2) 1.0 (0.5–1.6)†,§ 0.001
Absolute change in  
hAPV cm/s





 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016130. DOI: 10.1161/JAHA.120.016130 5
Murai et al CFC to Identify Coronary Flow Increase After PCI
discrimination improvement and net reclassification 
improvement values. Predictive factors for 50% in-
crease in coronary flow (R-hAPV ≥150%) were as-
sessed by using univariate and multivariate logistic 
regression analyses. FFR and iFR showed a signifi-
cant relationship in the present study (Spearman’s 
rho=0.87). Therefore, 2 multivariate models based 
on either FFR or iFR were made for clinical use. 
Associated variables in univariate analysis (P≤0.10) 
were entered into the final multivariate model. The 
statistical analysis was performed by using SPSS 
version 22.0 (SPSS, Inc., Chicago, IL) and R version 
3.5.3. A P value of <0.05 was considered statistically 
significant, using 2-tailed testing when applicable.
RESULTS
Baseline Characteristics
A total of 133 vessels were analyzed in this study (33 ves-
sels from DEFINE FLOW and 100 from the pooled da-
tabase). Nine subjects were missing either pre-PCI or 
post-PCI iFR. Clinical, angiographic, and physiological 
characteristics of this study are shown in Table 1. The me-
dian values of FFR, iFR, and CFR before PCI were 0.70 
(Q1–Q3: 0.56–0.80), 0.82 (Q1–Q3: 0.61–0.90), and 1.6 
(Q1–Q3: 1.3–2.1). There were no significant differences 
between pre- and post-PCI blood pressure (pre-PCI Pa 
at rest: 98±16 versus post-PCI Pa at rest: 99±16; P=0.30; 
pre-PCI Pa at hyperemia: 91±16 versus post-PCI Pa at 
hyperemia: 90±17; P=0.23). The median value of hAPV 
changed from 26.8 to 42.6 cm/s after PCI. The median 
value of R-hAPV was 149.4% (Q1–Q3: 112.6%–255.4%) 
and a R-hAPV ≥150% was observed in 66 vessels (49.6%).
Lesions classified by CFC before PCI were as fol-
lows: 14 normal CFC, 40 mildly reduced CFC, 31 mod-
erately reduced CFC, and 48 severely reduced CFC. 
Figure  1 shows the distribution plot of CFC grading. 
There were no significant differences in clinical variables 
among the groups with different CFC grading except 
for the use of calcium channel blockers and baseline 
percent diameter stenosis. Values of pre-PCI FFR and 
iFR showed considerable overlap among CFC classifi-
cations. After PCI, there were no significant differences 
in FFR, iFR, CFR, and CFC grading across the groups.
The Discriminating Efficacy of CFC for the 
Coronary Flow Increase in Comparison 
With CFR
Figure  2 shows the relationship between increase in 
coronary flow and pre-PCI CFR or CFC classification, 
and the individual coronary flow changes in each CFC 
grade are shown in Figure S1. Lesions with a greater 
impairment of CFC showed a larger increase in coro-
nary flow (R-hAPV: 104.2% for normal CFC; 125.9% 
for mildly reduced; 150.1% for moderately reduced; 
245.5% for severely reduced; P<0.001; Figure  2A). 
Using the same CFR distribution based on CFC criteria 
showed that only lesions with CFR corresponding to 
severely reduced CFC (CFR ≤1.7) had a significantly 
higher coronary flow increase after PCI (R-hAPV: 
97.4% for CFR in the normal zone; 126.6% for CFR in 
the mildly reduced zone; 133.3% for CFR in the mod-
erately reduced zone; 181.7% for CFR in the severely 
reduced zone; P=0.001; Figure 2B).
Diagnostic Efficacy Compared Between 
Conventional Physiological Indices and 
CFC Classification for the Vessels With 
Significant Coronary Flow Increase After 
PCI
Figure 3 shows the relationship between the pre-PCI 
values of conventional indices and hyperemic veloc-
ity change after PCI. All indices showed a signifi-
cant linear relationship with change in coronary flow. 
However, almost 40% of patients who underwent re-
vascularization in the present study did not achieve 
a significant increase in coronary flow after PCI even 
in lesions below the current cutoff values (Figure 4). 
Compared with conventional cutoff values of FFR 
Total, N=133










R-hAPV, % 149.4 (112.6–255.4) 104.2 (91.6 to 115.2)*,‡ 125.9 (95.9 to 151.4)*,‡ 150.1 (129.4–239.4)†,‡,§ 245.5 (168.9–423.8)*,†,§ <0.001
Vessels with R-hAPV 
>150%, n (%)
66 (49.6) 0 (0.0)*,‡ 10 (25.0)‡ 16 (51.6)‡,§ 40 (83.3)*,†,§ <0.001
ACE-I indicates angiotensin-converting enzyme inhibitor; APV, average peak coronary flow velocity; ARB, angiotensin receptor blocker; BMI, body mass 
index; CCB, calcium channel blocker; CFC, coronary flow capacity; CFR, coronary flow reserve; DS, diameter stenosis; FFR, fractional flow reserve; hAPV, 
hyperemic average peak flow velocity; iFR, instantaneous wave-free ratio; LAD, left anterior descending coronary artery; LCX, left circumflex artery; MLD, 
minimal lumen diameter; Pa, aortic pressure; PCI, percutaneous coronary intervention; Pd, distal coronary pressure; QCA, quantitative coronary angiography; 
RCA, right coronary artery; RD, reference diameter; and R-hAPV, ratio of post-PCI hAPV to pre-PCI.
*P<0.05 vs moderately reduced CFC.
†P<0.05 vs mildly reduced CFC.
‡P<0.05 vs severely reduced CFC.
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(≤0.80), iFR (≤0.89), and CFR (<2.0), the “ischemic” 
CFC (moderately to severely reduced CFC) showed 
numerically higher diagnostic accuracy with higher 
specificity to predict over 50% increase in coronary 
flow after PCI (accuracy and specificity: 75.2% and 
65.7% for ischemic CFC; 63.9% and 37.3% for FFR 
≤0.80; 67.7% and 42.9% for iFR ≤0.89; 63.2% and 
40.3% for CFR <2.0, Figure  4). Receiver operating 
characteristic curve analysis showed that a signifi-
cantly high predictive efficacy of CFC was detected 
in comparison with CFR, although there is no statisti-
cal difference between the conventional physiological 
indices (Figure 5). The concordance index of adding 
physiological cutoff values to angiographic stenosis 
severity revealed the incremental predictive efficacy 
of all physiological indices, although only CFR did not 
show statistical significance (Figure 6). Table 2 shows 
the results of the reclassification efficacy of ischemic 
CFC grading to predict the occurrence of significant 
coronary flow increase. Compared with conventional 
Figure 1. The distribution of CFC grading. 
CFC indicates coronary flow capacity; CFR, coronary flow reserve; and hAPV, hyperemic average peak 
flow velocity.
Figure 2. Change in coronary flow after PCI across CFC and CFR classification. 
A, classification according to CFC grading and (B) classification according to CFR grading based on the 
CFC criteria. CFC indicates coronary flow capacity; CFR, coronary flow reserve; and R-hAPV, ratio of 
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physiological indices-based classifications, all of the 
models integrated with CFC grading showed further 
increases in their incremental reclassification ability.
The Predictive Factors for the Significant 
Increase in Coronary Flow After PCI
The results of univariate and multivariate logistic re-
gression analysis to predict the lesions with R-hAPV 
≥150% are shown in Table  3. Only the factors with 
P≤0.10 assessed by univariate analysis are listed in 
the table. The multivariate analysis revealed that the 
independent predictors of significant coronary flow in-
crease were the lesions with ischemic CFC and FFR 
≤0.80 in the FFR model (ischemic CFC: odds ratio 
[OR], 10.3; 95% CI, 4.3–24.7; P<0.001; and FFR: OR, 
5.5; 95% CI, 1.9–16.2; P=0.002) and ischemic CFC 
and iFR ≤0.89 in the iFR model (ischemic CFC: OR, 
14.5; 95% CI, 5.5–38.3; P<0.001; and iFR: OR, 12.5; 
95% CI, 3.5–44.3; P<0.001).
DISCUSSION
The major findings of our study are as follows: (1) CFC 
grading improved the discriminating ability to predict 
coronary flow increase after PCI in comparison with 
conventional CFR; (2) ischemic CFC showed the high 
predictive performance with high sensitivity for a sig-
nificant increase in coronary flow compared with the 
conventional cutoff values for FFR, iFR, and CFR; and 
(3) CFC provided additional information for predicting 
which lesions had an increase in coronary flow after PCI 
when accounting for conventional physiology-based 
Figure 3. The relationships between pre-PCI values of conventional physiological indices and change in coronary flow 
after PCI.
CFC indicates coronary flow capacity; CFR, coronary flow reserve; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; 
PCI, percutaneous coronary intervention; and R-hAPV, ratio of post-PCI hyperemic average peak flow velocity to pre-PCI.
Figure 4. Prevalence of significant increase in coronary flow after PCI in the classification based 
on the cutoff value of the various physiological indices. 
CFC indicates coronary flow capacity; CFR, coronary flow reserve; FFR, fractional flow reserve; iFR, 
instantaneous wave-free ratio; NPV, negative predictive value; PPV, positive predictive value; and R-hAPV, ratio 
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decision making. These results justify the use of CFC 
grading in clinical practice.
The Superiority of Coronary Flow 
Capacity as a Comprehensive 
Assessment of Coronary Circulation to 
Predict Coronary Flow Increase After PCI
The ORBITA (Percutaneous Coronary Intervention in 
Stable Angina) trial raised doubt with respect to the 
effect of revascularization on angina symptoms in 
chronic coronary syndrome.19 Recently, the clinical 
outcomes of the ISCHEMIA (International Study of 
Comparative Health Effectiveness With Medical and 
Invasive Approaches) trial, the latest randomized trial 
to investigate the further benefit of revascularization 
compared with optimal medical therapy in patients 
with chronic coronary syndrome were reported.20 
Compared with an initial medical strategy, an initial 
revascularization strategy did not demonstrate a risk 
reduction for adverse cardiovascular events over me-
dian 3 years. Based on the insight from the recent ran-
domized trials, a physiologic rationale has been more 
strongly required before undertaking revascularization 
for coronary artery disease in patients with chronic 
coronary syndrome. An increase in coronary flow is the 
most fundamental rationale behind revascularization. 
Coronary intervention without corresponding coronary 
flow increase would not be expected to improve patient 
outcomes and could even be harmful.2,21 Therefore, 
we need accurate methods to identify lesions with the 
best potential for coronary flow increase after PCI.
The previous studies showed that not only reduc-
tion in resistance of epicardial artery lesions but also 
improvement in coronary microcirculation after PCI 
are important factors for coronary flow increase.6,22 
Based on this insight, comprehensive assessment 
of the whole coronary circulation can be a favorable 
indicator for “effective” revascularization with respect 
to coronary flow increase.7 CFR has been a represen-
tative index as a comprehensive assessment for the 
coronary circulation and has provided predictive effi-
cacy for long-term adverse events.9,10,23 However, the 
dependence of CFR on resting hemodynamics can 
Figure 5. Receiver operating characteristic curve analysis 
for predicting significant coronary flow increase by 
intracoronary physiological indices.
*P<0.05 in comparison with CFC. AUC indicates area under the 
curve; CFC, coronary flow capacity; CFR, coronary flow reserve; 
FFR, fractional flow reserve; and iFR, instantaneous wave-free ratio.
Figure 6. Improvement in C-index by adding the cutoff value of each physiological index to angiographic stenosis severity. 
*P<0.05, difference in comparison with QCA %DS+CFR<2.0. %DS indicates percent diameter stenosis; C-index, concordance 
index; CFC, coronary flow capacity; CFR, coronary flow reserve; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; 
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diminish its discriminating efficacy. Receiver operating 
characteristic curve analysis demonstrated that CFR 
was not superior for identification of vessels with cor-
onary flow increase after PCI compared with FFR or 
iFR which are regarded as specific assessments for 
epicardial coronary artery stenosis (Figure 5; FFR ver-
sus iFR, P=0.74; FFR versus CFR, P=0.17; iFR versus 
CFR, P=0.06). In line with our hypothesis, CFC as a 
modified flow-based comprehensive assessment of 
coronary circulation showed higher discriminating effi-
cacy than CFR (P=0.013). Meanwhile, that of CFC was 
numerically higher but comparable with FFR and iFR 
(CFC versus FFR, P=0.67; CFC versus iFR, P=0.79). 
However, compared with the current cutoff values of 
FFR or iFR, ischemic CFC demonstrated high specific-
ity to predict significant coronary flow increase, which 
might reduce unnecessary revascularization. Our find-
ings add further rationale for CFC-guided decision 
making.
Clinical Implication of CFC Grading in the 
Current Physiological Treatment Strategy
The cutoff value of FFR=0.80 is commonly used 
for clinical decision making. However, previous 
studies revealed that the occurrence of adverse 
clinical events is associated with FFR values as a 
continuous variable, and many lesions around the 
FFR cutoff value do not need revascularization.2,24 
In line with this concern, the established FFR cutoff 
value=0.80 showed rather low specificity but very 
high sensitivity to predict a significant increase in 
coronary flow in the present study (Figure 4). This 
would be attributable to the design of current cri-
terion of FFR-based decision making to avoid 
missing the patients who might benefit from re-
vascularization. Thus, a considerable number of 
unnecessary revascularizations that cannot obtain 
a significant coronary flow increase might be per-
formed when the treatment decision is made based 
on the FFR=0.80 cutoff value. In the present study, 
the best cutoff values of FFR or iFR assessed by 
receiver operating characteristic curve were much 
lower than the current clinically used cutoff values 
(the best cutoff values: ≤0.68 for FFR; <0.80 for 
iFR). Their predictive efficacies were similar to CFC 
classification (Figure S2), although their high sensi-
tivities were reduced. The best cutoff value of FFR 
was close to the estimated cutoff point of FFR for 
superiority of revascularization to medical therapy 
(FFR ≤0.67), which was reported by the previous 
meta-analysis.2 These findings might suggest that 
the current physiological cutoff points could be re-
considered for optimizing revascularization crite-
ria. Of note, current CFC classification, which has 
already shown the clinical efficacy in deferral pa-
tients,12 provided further discriminating efficacy with 
high specificity for the lesions with coronary flow 
increase after PCI. In addition, lesions with severely 
reduced CFC showed high specificity for predicting 
improvement (Figure  4). This high predictive value 
of severely reduced CFC still remained even when 
limiting the lesions around conventional FFR cutoff 
Table 2. The Incremental Reclassification Ability of CFC 
to Predict the Significant Coronary Flow Increase
Prediction Model NRI P Value IDI P Value
FFR
FFR+CFC 1.010 <0.001 0.121 <0.001
iFR
iFR+CFC 1.070 <0.001 0.118 <0.001
CFR
CFR+CFC 0.708 <0.001 0.103 <0.001
CFC indicates coronary flow capacity; CFR, coronary flow reserve; FFR, 
fractional flow reserve; IDI, integrated discrimination improvement; iFR, 
instantaneous wave-free ratio; and NRI, net reclassification improvement.
Table 3. Univariate and Multivariate Logistic Regression Analyses of FFR and iFR Models to Predict the Significant 






OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
Diabetes mellitus 0.494 0.231–1.056 0.069
Use of statin 1.781 0.896–3.543 0.100
QCA RD 1.862 0.937–3.701 0.076
QCA %DS 1.051 1.019–1.083 0.002
FFR ≤0.80 5.952 2.247–15.771 <0.001 5.497 1.860–16.243 0.002
iFR ≤0.89 10.581 3.424–32.694 <0.001 12.499 3.530–44.262 <0.001
CFR <2.0 4.275 1.816–10.061 0.001
Moderately to severely 
reduced CFC
10.713 4.621–24.837 <0.001 10.261 4.269–24.665 <0.001 14.514 5.502–38.285 <0.001
CFC indicates coronary flow capacity; CFR, coronary flow reserve; DS, diameter stenosis; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; 




 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016130. DOI: 10.1161/JAHA.120.016130 10
Murai et al CFC to Identify Coronary Flow Increase After PCI
values (FFR 0.70–0.85; Figure S3). Furthermore, this 
study demonstrated an incremental reclassifica-
tion ability of CFC over conventional indices. These 
findings suggest that CFC, like additional benefit 
of CFR in FFR-based treatment strategy,23 could 
yield incremental useful information for our decision 
making, although further investigations are needed.
Limitations
The present study assessed the change in coronary 
flow just after revascularization. Further change in 
coronary circulation might occur during the long-
term follow-up.25,26 Therefore, this acute change in 
coronary flow observed in this study might not show 
the long-term effects of revascularization on coro-
nary circulation. In the present study, assessment 
of coronary flow is derived from not flow itself but 
velocity. It depends on the assessment location of 
coronary artery or vessel size. Nonpaired compari-
son of coronary flow velocity between different pa-
tients is apparently limited in its ability to interpret the 
individual increase in flow volume. Therefore, in the 
present study, we used serial measurements of cor-
onary flow velocity in each patient and the flow ratio 
of after PCI to before PCI for evaluating coronary flow 
change, which might at least partially alleviate this 
limitation. Despite this, one of the important limita-
tions of this study is the lack of the assessment of 
absolute increase in coronary flow volume. Although 
coronary flow volume also depends on the assess-
ment location and downstream myocardial mass. 
The lesions with greater subtended cardiac mass that 
could provide the greater increase in flow volume by 
revascularization would be associated with greater 
requirement for revascularization. Thus, change in 
coronary flow volume would be another important 
marker of effectiveness of revascularization. The 
lack of this important information might make it dif-
ficult for us to understand the true predictive efficacy 
of CFC including its prognostic value. The present 
study contained these limitations, and further stud-
ies are needed to test including flow volume as-
sessment and if CFC-based decision making may 
provide prognostic information in relation to coronary 
flow increase. In the present study, 31 vessels with 
pre-PCI FFR values over 0.80 (23.3%) underwent PCI 
according to the operator’s discretion, guided by low 
CFR (19 cases [14.3%]) or clinical and angiographic 
findings (12 cases [9.0%]), although these vessels are 
rarely treated in the current physiology-based treat-
ment strategy. However, CFC remains the strong-
est predictor even when limiting the analysis to FFR 
≤0.8 (Table S1). We defined over 150% R-hAPV as 
the threshold of significant increase in coronary flow 
after PCI. The previous meta-analysis reported that 
the FFR value of 0.67 is the threshold for the greater 
benefit of PCI over that of medication.2 In the present 
study, 82% of the lesions with FFR ≤0.67 (n=55 le-
sions) showed over 50% increase of coronary flow 
(median R-hAPV: 239.4% [Q1–Q3: 180.3%–419.8%]). 
This result would support the appropriateness of our 
definition of significant increase in coronary flow. 
However, further studies are required to investigate 
the relationship between long-term outcomes and 
increase in coronary flow after PCI. This study was 
made of 2 data sets from the studies with slightly 
different inclusion criteria. Regarding to each intrasu-
bset difference in the prevalence of R-hAPV ≥150% 
between ischemic CFC and nonischemic CFC, in line 
with our main result, ischemic CFC showed a higher 
prevalence than nonischemic CFC in IDEAL subset 
(76.3% for ischemic CFC versus 17.1% for nonis-
chemic CFC; P<0.001; Figure  S4). In the DEFINE 
FLOW subset, the prevalence of significant flow 
increase in vessels with ischemic CFC was higher 
but not statistically significant compared with that of 
nonischemic CFC (55.0% for ischemic CFC versus 
23.1% for nonischemic CFC, P=0.087). This differ-
ence in the prevalence of significant flow increase 
between the 2 studies might be attributable to the 
small number of cases in the DEFINE FLOW subset 
and/or selection bias because the only patients with 
FFR ≤0.80 in DEFINE FLOW study underwent PCI 
according to the protocol. However, when limiting the 
analysis in the lesions with FFR ≤0.80, CFC classifi-
cation also showed the only independent predictor 
(Table S1). Intracoronary Doppler flow-based CFC is 
purely a flow velocity–based assessment. Therefore, 
these findings would also lend a rationale to treat 
the lesions according to CFC grading assessed by 
noninvasive imaging using myocardial blood flow. 
However, collateral flow was not taken into consid-
eration, whereas 42 lesions (31.6%) showed FFR 
<0.60. Therefore, the potential benefit of PCI only 
by improvement of epicardial coronary flow veloc-
ity might be overestimated in such severe stenoses. 
This might lead to some different outcomes of CFC 
grading between invasive and noninvasive methods. 
Finally, although this is a relatively large study of the 
direct assessment for coronary flow change using in-
tracoronary Doppler flow measurements before and 
after PCI, the number of cases in the present study 
might be still underpowered to draw the conclusion.
CONCLUSIONS
CFC showed a significant improvement of diagnostic 
efficacy for identification of lesions with a significant 
increase in coronary flow after revascularization com-
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specificity would provide the useful information in the 
treatment strategy based on the current cutoff values 
of conventional physiological indices. This study pro-
vides a physiological rationale for revascularization of 
lesions guided by ischemic CFC.
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Table S1. Univariate and multivariate logistic regression analyses to predict the 
significant increase in coronary flow increase in the vessels with FFR≤0.80 
 Univariate logistic regression  Multivariate logistic regression 
 OR 95% CI p  OR 95% CI p 
QCA %DS 1.050 1.014–1.088 0.007     
iFR≤0.89 12.419 1.460–105.666 0.021     
CFR<2.0 3.148 1.219–8.132 0.018     
moderately-severely 
reduced CFC 
10.200 3.949–26.347 <0.001     
Severely reduced 
CFC 
16.409 5.163–52.153 <0.001  30.00 6.540–137.606 <0.001 
 
CFC indicates coronary flow capacity; CFR, coronary flow reserve; DS, diameter stenosis; FFR, 














CFC indicates coronary flow capacity; hAPV, hyperemic average peak flow velocity; PCI, 










Figure S2. Prevalence of significant increase in coronary flow after PCI based on the 
















CFC indicates coronary flow capacity; CFR, coronary flow reserve; iFR, instantaneous wave-
free ratio; R-hAPV, ratio of post-PCI hAPV to pre-PCI. R-hAPV >150% was defined as the 














CFC indicates coronary flow capacity; R-hAPV, ratio of post-PCI hAPV to pre-PCI. R-hAPV 
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